Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Nganou Makamdop, Krystelle ^a   Van Roosmalen, Maarten L ^b   Audouy, Sandrine Al ^c   Van Gemert, Geert Jan ^a   Leenhouts, Kees ^b   Hermsen, Cornelus C ^a   Sauerwein, Robert W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Mucosis BV   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

B.L.P.; CSP; Delivery platform; Immunization; Malaria; Plasmodium berghei

Indexed keywords

CIRCUMSPOROZOITE PROTEIN; EPITOPE; GAMMA INTERFERON; CIRCUMSPOROZOITE PROTEIN, PROTOZOAN; MALARIA VACCINE; PROTOZOAL PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BACTERIUM LIKE PARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LACTOCOCCUS LACTIS; MALARIA; MOUSE; NONHUMAN; ORGANISM FORMS; PARASITEMIA; PLASMODIUM BERGHEI; ANIMAL; BACTERIUM; BAGG ALBINO MOUSE; GENETICS; IMMUNOLOGY;

ANIMALS; BACTERIA; EPITOPES; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; PLASMODIUM BERGHEI; PROTOZOAN PROTEINS;

EID: 84857126472     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-50     Document Type: Article

References (45)

1. WHO, World Malaria Report 2010 World Health Organization, Geneva 2010
2. Prime-boost vectored malaria vaccines: progress and prospects. Hill AV, Reyes-Sandoval A, O'Hara G, Ewer K, Lawrie A, Goodman A, Nicosia A, Folgori A, Colloca S, Cortese R, Gilbert SC, Draper SJ, Hum Vaccin 2010 6 78 83 10.4161/hv.6.1.10116 20061802
3. New concepts in vaccine development in malaria. Kanoi BN, Egwang TG, Curr Opin Infect Dis 2007 20 311 316 10.1097/QCO.0b013e32816b5cc2 17471043 (Pubitemid 46686015)
4. Viral vectors in malaria vaccine development. Limbach KJ, Richie TL, Parasite Immunol 2009 31 501 519 10.1111/j.1365-3024.2009.01141.x 19691555
5. Circumsporozoite proteins of malaria parasites. Nussenzweig V, Nussenzweig RS, Cell 1985 42 401 403 10.1016/0092-8674(85)90093-5 2411417
6. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparu malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Birkett A, Dubovsky F, Tierney E, Gleiter CH, Boehmer G, Luty AJ, Ramharter M, Thornton GB, Kremsner PG, Nardin EH, Infect Immun 2005 73 3587 3597 10.1128/IAI.73.6.3587-3597.2005 15908388 (Pubitemid 40745903)
7. Phase 1 safety and immunogenicity trial of malaria vaccine RTS, S/AS02A in adults in a hyperendemic region of western Kenya. Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR, Am J Trop Med Hyg 2006 75 166 170 16837726 (Pubitemid 351627588)
8. Protective immunity induced with malaria vaccine, RTS, S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. Sun P, Schwenk R, White K, Stoute JA, Cohen J, Ballou WR, Voss G, Kester KE, Heppner DG, Krzych U, J Immunol 2003 171 6961 6967 14662904 (Pubitemid 37532133)
9. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparu circumsporozoite protein. Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, Berthoud T, Andrews L, Andersen RF, Moore A, Gilbert SC, Poulton I, Dubovsky F, Tierney E, Correa S, Huntcooke A, Butcher G, Williams J, Sinden RE, Hill AV, Infect Immun 2006 74 2706 2716 10.1128/IAI.74.5.2706-2716.2006 16622207 (Pubitemid 43672979)
10. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, Hill AV, Vaccine 2002 20 1039 1045 10.1016/S0264-410X(01)00450-9 11803063 (Pubitemid 34135938)
11. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Hutchings CL, Birkett AJ, Moore AC, Hill AV, Infect Immun 2007 75 5819 5826 10.1128/IAI.00828-07 17908809 (Pubitemid 350207821)
12. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Murata K, Garcia-Sastre A, Tsuji M, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Palese P, Esteban M, Zavala F, Cell Immunol 1996 173 96 107 10.1006/cimm.1996.0255 8871605 (Pubitemid 26344926)
13. Protection from Plasmodium berghe infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Plebanski M, Gilbert SC, Schneider J, Hannan CM, Layton G, Blanchard T, Becker M, Smith G, Butcher G, Sinden RE, Hill AV, Eur J Immunol 1998 28 4345 4355 10.1002/(SICI)1521-4141(199812)28:12<4345::AID- IMMU4345>3.0.CO;2-P 9862371 (Pubitemid 28558665)
14. Robertson MN; Step Study Protocol Team: Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Lancet 2008 372 1881 1893 10.1016/S0140-6736(08)61591-3 19012954
15. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, Buist G, Kok J, Kuipers OP, Robillard G, Leenhouts K, Appl Environ Microbiol 2006 72 880 889 10.1128/AEM.72.1.880-889.2006 16391130
16. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. van Roosmalen ML, Kanninga R, El KM, Neef J, Audouy S, Bosma T, Kuipers A, Post E, Steen A, Kok J, Buist G, Kuipers OP, Robillard G, Leenhouts K, Methods 2006 38 144 149 10.1016/j.ymeth.2005.09. 015 16414272 (Pubitemid 43163475)
17. Lactococcus lacti GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Audouy SA, van Roosmalen ML, Neef J, Kanninga R, Post E, van DM, Metselaar H, van SS, Robillard GT, Leenhouts KJ, Hermans PW, Vaccine 2006 24 5434 5441 10.1016/j.vaccine.2006.03.054 16757068 (Pubitemid 43831375)
18. LysM, a widely distributed protein motif for binding to (peptido)glycans. Buist G, Steen A, Kok J, Kuipers OP, Mol Microbiol 2008 68 838 847 10.1111/j.1365-2958.2008.06211.x 18430080 (Pubitemid 351581067)
19. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. Saluja V, Amorij JP, van Roosmalen ML, Leenhouts K, Huckriede A, Hinrichs WL, Frijlink HW, AAPSJ 2010 12 109 116 10.1208/s12248-009-9168-2 20058113
20. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. Saluja V, Visser MR, Ter VW, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW, Vaccine 2010 28 7963 7969 10.1016/j.vaccine.2010.09.066 20946860
21. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lacti vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, Leenhouts K, Pasetti MF, Mucosal Immunol 2010 3 159 171 10.1038/mi.2009.131 19924118
22. Development of lactococcal GEM-based pneumococcal vaccines. Audouy SA, van SS, van Roosmalen ML, Post E, Kanninga R, Neef J, Estevao S, Nieuwenhuis EE, Adrian PV, Leenhouts K, Hermans PW, Vaccine 2007 25 2497 2506 10.1016/j.vaccine.2006.09.026 17081660 (Pubitemid 46366131)
23. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K, Vaccine 2006 24 3900 3908 10.1016/j.vaccine.2006.02.040 16545511
24. Autoregulation of nisin biosynthesis in Lactococcus lacti by signal transduction. Kuipers OP, Beerthuyzen MM, de Ruyter PG, Luesink EJ, de Vos WM, JBiolChem 1995 270 27299 27304
25. Nes IF. Holo H, High-frequency transformation by electroporation of Lactococcus lactis subsp cremoris grown with glycine in osmotically stabilized media Appl Environ Microbiol 1989 55 3119 3123
26. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghe. Meraldi V, Audran R, Romero JF, Brossard V, Bauer J, Lopez JA, Corradin G, Vaccine 2003 21 2485 2491 10.1016/S0264-410X(03)00093-8 12744882 (Pubitemid 36561340)
27. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghe together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites. Meraldi V, Romero JF, Kensil C, Corradin G, Vaccine 2005 23 2801 2812 10.1016/j.vaccine.2004.10.044 15780728 (Pubitemid 40381274)
28. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V, Zavala F, Nature 1989 341 323 326 10.1038/341323a0 2477703 (Pubitemid 20102099)
29. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT, Vaccine 2004 22 3575 3584 10.1016/j.vaccine.2004.03.050 15315836 (Pubitemid 39099633)
30. Potentiation by a novel alkaloid glycoside adjuvant of a protective cytotoxic T cell immune response specific for a preerythrocytic malaria vaccine candidate antigen. Heal KG, Sheikh NA, Hollingdale MR, Morrow WJ, Taylor-Robinson AW, Vaccine 2001 19 4153 4161 10.1016/S0264-410X(01)00166-9 11457540 (Pubitemid 32703635)
31. Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghe with the modified heat-labile toxin of Escherichia col (LTK63) induces a complete protection against malaria challenge. Romero JF, Ciabattini A, Guillaume P, Frank G, Ruggiero P, Pettini E, Del GG, Medaglini D, Corradin G, Vaccine 2009 27 1266 1271 10.1016/j.vaccine.2008.12.010 19111883
32. Synthetic peptide vaccine confers protection against murine malaria. Zavala F, Tam JP, Barr PJ, Romero PJ, Ley V, Nussenzweig RS, Nussenzweig V, J Exp Med 1987 166 1591 1596 10.1084/jem.166.5.1591 3316473 (Pubitemid 18051448)
33. Immunogenicity of synthetic peptides from circumsporozoite protein of Plasmodium falciparu. Ballou WR, Rothbard J, Wirtz RA, Gordon DM, Williams JS, Gore RW, Schneider I, Hollingdale MR, Beaudoin RL, Maloy WL, Science 1985 228 996 999 10.1126/science.2988126 2988126 (Pubitemid 15028388)
34. Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghe. Romero PJ, Tam JP, Schlesinger D, Clavijo P, Gibson H, Barr PJ, Nussenzweig RS, Nussenzweig V, Zavala F, Eur J Immunol 1988 18 1951 1957 10.1002/eji.1830181213 2464495 (Pubitemid 19046210)
35. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus Vaccine. Oliveira-Ferreira J, Miyahira Y, Layton GT, Savage N, Esteban M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Zavala F, 2000 18 1863 1869
36. Complete protection against P berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid Vaccine. Tartz S, Russmann H, Kamanova J, Sebo P, Sturm A, Heussler V, Fleischer B, Jacobs T, 2008 26 5935 5943
37. Heterologous expression of plasmodial proteins for structural studies and functional annotation. Birkholtz LM, Blatch G, Coetzer TL, Hoppe HC, Human E, Morris EJ, Ngcete Z, Oldfield L, Roth R, Shonhai A, Stephens L, Louw AI, Malar J 2008 7 197 10.1186/1475-2875-7-197 18828893
38. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. Tam JP, Clavijo P, Lu YA, Nussenzweig V, Nussenzweig R, Zavala F, J Exp Med 1990 171 299 306 10.1084/jem.171.1.299 1688609 (Pubitemid 20040615)
39. Safety, immunogenicity, and efficacy of Plasmodium falciparu repeatless circumsporozoite protein vaccine encapsulated in liposomes. Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W, Krzych U, Schneider I, Wirtz RA, Richards RL, Trofa A, Hall T, Sadoff JC, Boerger P, Alving CR, Sylvester DR, Porter TG, Ballou WR, J Infect Dis 1996 174 361 366 10.1093/infdis/174.2.361 8699067 (Pubitemid 26251423)
40. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparu circumsporozoite protein-based vaccine. Schwenk R, Asher LV, Chalom I, Lanar D, Sun P, White K, Keil D, Kester KE, Stoute J, Heppner DG, Krzych U, Parasite Immunol 2003 25 17 25 10.1046/j.1365-3024.2003.00495.x 12753434 (Pubitemid 38019095)
41. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparu infection and disease. Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, Doherty T, Plebanski M, Akinwunmi P, Everaere S, Watkins KR, Voss G, Tornieporth N, Alloueche A, Greenwood BM, Kester KE, McAdam KP, Cohen J, Hill AV, Nat Med 2004 10 406 410 10.1038/nm1009 15034567 (Pubitemid 38508520)
42. The synthetic, oxidized C-terminal fragment of the Plasmodium berghe circumsporozoite protein elicits a high protective response. Roggero MA, Meraldi V, Lopez JA, Eberl G, Romero JC, Matile H, Betschart B, Corradin G, Renggli J, Eur J Immunol 2000 30 2679 2685 10.1002/1521-4141(200009)30:9<2679::AID- IMMU2679>3.0.CO;2-# 11009102
43. Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. Grüner AC, Mauduit M, Tewari R, Romero JF, Depinay N, Kayibanda M, Lallemand E, Chavatte JM, Crisanti A, Sinnis P, Mazier D, Corradin G, Snounou G, Rénia L, PLoSOne 2007 2 1371
44. Minimal role for the circumsporozoite protein in the induction of sterile immunity by vaccination with live rodent malaria sporozoites. Mauduit M, Tewari R, Depinay N, Kayibanda M, Lallemand E, Chavatte JM, Snounou G, Renia L, Grüner AC, InfectImmun 2010 78 2182 2188
45. Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Mishra S, Rai U, Shiratsuchi T, Li X, Vanloubbeeck Y, Cohen J, Nussenzweig RS, Winzeler EA, Tsuji M, Nussenzweig V, Vaccine 2011 29 7335 7342 10.1016/j.vaccine.2011.07.081 21807053